The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Open accessAbstract
BACKGROUND: The incidence of hematologic cancers increases with age. These cancers are associated with recurrent somatic mutations in specific genes. We hypothesized that such mutations would be detectable in the blood of some persons who are not known to have hematologic disorders. METHODS: We analyzed whole-exome sequencing data from DNA in the peripheral-blood cells of 17,182 persons who were unselected for hematologic phenotypes. We looked for somatic mutations by identifying previously characterized single-nucleotide variants and small insertions or deletions in 160 genes that are recurrently mutated in hematologic cancers. The presence of mutations was analyzed for an association with hematologic phenotypes, survival, and cardiovascular events. RESULTS: Detectable somatic mutations were rare in persons younger than 40 years of age but rose appreciably in frequency with age. Among persons 70 to 79 years of age, 80 to 89 years of age, and 90 to 108 years of age, these clonal mutations were observed in 9.5% (219 of 2300 persons), 11.7% (37 of 317), and 18.4% (19 of 103), respectively. The majority of the variants occurred in three genes: DNMT3A, TET2, and ASXL1. The presence of a somatic mutation was associated with an increase in the risk of hematologic cancer (hazard ratio, 11.1; 95% confidence interval [CI], 3.9 to 32.6), an increase in all-cause mortality (hazard ratio, 1.4; 95% CI, 1.1 to 1.8), and increases in the risks of incident coronary heart disease (hazard ratio, 2.0; 95% CI, 1.2 to 3.4) and ischemic stroke (hazard ratio, 2.6; 95% CI, 1.4 to 4.8). CONCLUSIONS: Age-related clonal hematopoiesis is a common condition that is associated with increases in the risk of hematologic cancer and in all-cause mortality, with the latter possibly due to an increased risk of cardiovascular disease. (Funded by the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Mutations in DNMT3A and TET2 account for over 90% of CH cases2,6”
From TET2-mutant myeloid cells mitigate Alzheimer’s disease progression via CNS infiltration and enhanced phagocytosis in mice (2025) · cites this paper as [2]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CHIP has emerged as a clinically relevant state associated with increased all-cause mortality and a broad spectrum of non-malignant diseases, most prominently atherosclerotic cardiovascular disease and stroke [1,4,5].”
From Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, progression to hematological malignancies depends on the type and complexity of mutations in CHIP.2,5,6”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function heterozygous mutations in epigenetic regulators DNMT3A (cytosine methyltransferase) and TET2 (methylcytosine dioxygenase) are the most frequently detected mutations in CHIP, accounting for about 50% to 60% and 10% to 30% of mutations found in CHIP carriers, respectively.1, 2, 3,7,8”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function heterozygous mutations in epigenetic regulators DNMT3A (cytosine methyltransferase) and TET2 (methylcytosine dioxygenase) are the most frequently detected mutations in CHIP, accounting for about 50% to 60% and 10% to 30% of mutations found in CHIP carriers, respectively.1, 2, 3,7,8”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“More important, advanced age is the best predictor of CHIP, with a 5.6% or 18.4% prevalence in the sixth or ninth decade of life, respectively.2”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“are predicted to have high expansion rates (10% increase in mean VAF per year1, 2, 3,7)”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Clone size, which is approximated by the variant allele fraction (VAF), has previously been shown to be an important predictor of risk for blood cancer1,17 and cardiovascular outcomes8,9.”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Despite its hematologically silent nature, CH has been associated with increased mortality and morbidity [1,32].”
From Clonal hematopoiesis and inflammation – the perpetual cycle (2023) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“although increased red cell distribution width (RDW) has been reported (Jaiswal et al., 2014).”
From Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNγ signaling (2021) · cites this paper as Jaiswal et al., 2014
The cited source says what the claim attributes to it.
In the citing paper
“This state of abnormal HSC expansion without overt hematologic disease is known as clonal hematopoiesis (CH), and is associated with increased risk of cardiovascular events and blood cancers (3)(4)(5).”
From Txnip Enhances Fitness of Dnmt3a -Mutant Hematopoietic Stem Cells via p21 (2022) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Instead, the discovery of widespread clonal expansions in ageing human tissues19,50–52 raises the possibility that some somatic mutations contribute to ageing by driving clonal expansions of functionally altered cells at a cost to the organism49,53,54.”
From Somatic mutation rates scale with lifespan across mammals (2022) · cites this paper as [50]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Methods adhered to published guidelines 77 .”
From Clonal hematopoiesis-associated motoric deficits caused by monocyte-derived microglia accumulating in aging mice (2025) · cites this paper as [77]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The isolated effects of individual inflammatory cytokines, including type 1 interferons (IFNa/b) 1-3 , type 2 IFN (IFNg) 4-6 , TNFa 7,8 , and IL-1 9-11 , have been well-documented in mouse hematopoietic development.”
From Type 1 interferon perturbates clonal competition by reshaping human blood development (2026) · cites this paper as [2]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Interestingly, while IFNa alters mouse HSC marker Sca-1 2 (rendering difficult the quantification of progenitor cell frequency changes by flow cytometric assessment in mice), IFNa did not alter CD90 expression after treatment in the HSPCs ( Fig. 2e, Supplementary Fig. 3c ).”
From Type 1 interferon perturbates clonal competition by reshaping human blood development (2026) · cites this paper as [2]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previously, induction of IFNa in mice have yielded mixed results demonstrating either an upregulation 2 or downregulation 53 of TNFa.”
From Type 1 interferon perturbates clonal competition by reshaping human blood development (2026) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“clonal hematopoiesis is a frequent event in elderly people.”
From Aging of hematopoietic stem cells (2018) · cites this paper as [76]
In the citing paper
“Epigenetic genes that are relatively frequently affected in these conditions include DNMT3A, EZH2, TET2, and SETDB1.”
From Aging of hematopoietic stem cells (2018) · cites this paper as [76]
In the citing paper
“The phenomenon also appears to be counterintuitively well tolerated, where HSCs containing oncogenic mutations can overtake most of the hematopoietic system without transforming into leukemia (Jaiswal et al., 2014).”
From Unraveling Hematopoiesis through the Lens of Genomics (2020) · cites this paper as Jaiswal et al., 2014
In the citing paper
“The size of these mutant clones was massive; in one study, a median of ~18% of blood cells carried the mutations 28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“For example, CHIP has been reported to be more common in older men 28 and smokers 27 and less common in Hispanics 28, although these associations are all relatively modest.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Indeed, in population-based cohorts that underwent exome sequencing, the presence of CHIP was associated with ~10-fold increased relative risk of these malignancies over several years of follow-up 27,28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“CHIP itself does not denote a malignancy, nor is it associated with clinically significant alterations in blood counts 28,63.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“In an initial study, this risk could not be explained by cancer deaths but was instead related to increased cardiovascular mortality 28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“In one study, 4% of CHIP carriers developed a blood cancer over the subsequent 8 years, corresponding to ~0.5% of CHIP cases converting to malignancy per year 28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Several studies have found that CHIP is associated with a 30–40% increased mortality risk 27,28,37.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Myeloid malignancies were most common, although some people with CHIP did develop lymphoid cancers 27,28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Indeed, some individuals with clonal hematopoiesis have virtually all of their blood cells arising from a single mutated HSC 28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“CHIP has been found to be associated with a 30% increase in the likelihood of having type 2 diabetes (T2D) 28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Studies of serial samples have shown that the trajectory of a clone can vary between people.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Some people have clones that remain stagnant in size for many years, whereas other people have clones that show steady growth 28,33.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“These findings are supported by recent findings demonstrating a causal link between mutations in HSPCs in the context of clonal hematopoiesis with indeterminate origin and altered transcriptional output of macrophages, which affect the vascular wall and contributes to atherosclerosis.83,84”
From Inflammatory bone marrow microenvironment (2019) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,965
Self-citationInflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Inflammation in Atherosclerosis
Libby, P. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179705 · Cited by 3,796
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Self-citationMacrophages, inflammation, and insulin resistance
Olefsky, J. M., & Glass, C. K. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135846 · Cited by 2,733
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Flagged first, then by citations
1 of the 48 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 601–700 of 1,023
Gao, T., Ptashkin, R. N., Bolton, K. L., Sirenko, M., Fong, C., Spitzer, B. G., Menghrajani, K. N., Ossa, J. A., Zhou, Y., Bernard, E., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20565-7 · Cited by 100
Bernstein, N., Chapman, M. S., Nyamondo, K., Chen, Z., Williams, N., Mitchell, E., Campbell, P. J., Cohen, R. L., & Nangalia, J. (2024) · Nature Genetics · doi:10.1038/s41588-024-01755-1 · Cited by 108
BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features
Neuendorff, N. R., Burmeister, T., Dörken, B., & Westermann, J. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2721-z · Cited by 98
Danielsson, M., Halvardson, J., Davies, H., Moghadam, B. T., Mattisson, J., Rychlicka-Buniowska, E., Jaszczyński, J., Heintz, J., Lannfelt, L., Giedraitis, V., et al. (2019) · European Journal of Human Genetics · doi:10.1038/s41431-019-0533-z · Cited by 96
The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments
Capua, D. D., Bracken-Clarke, D. M., Ronan, K. E., Baird, A., & Finn, S. P. (2021) · Cancers · doi:10.3390/cancers13163923 · Cited by 98
Telomeres and Age-Related Diseases
Gruber, H., Semeraro, M. D., Renner, W., & Herrmann, M. (2021) · Biomedicines · doi:10.3390/biomedicines9101335 · Cited by 102
Wnt activity and basal niche position sensitize intestinal stem and progenitor cells to DNA damage
Tao, S., Tang, D., Morita, Y., Sperka, T., Omrani, O., Lechel, A., Sakk, V., Kraus, J. M., Kestler, H. A., Kühl, M., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490700 · Cited by 98
TET2 binding to enhancers facilitates transcription factor recruitment in hematopoietic cells
Rasmussen, K. D., Berest, I., Keβler, S., Nishimura, K., Simón-Carrasco, L., Vassiliou, G. S., Pedersen, M. T., Christensen, J., Zaugg, J. B., & Helin, K. (2019) · Genome Research · doi:10.1101/gr.239277.118 · Cited by 95
El-Khoury, H., Lee, D. J., Alberge, J.-B., Redd, R., Cea-Curry, C. J., Perry, J., Barr, H., Murphy, C., Sakrikar, D., Barnidge, D., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00069-2 · Cited by 94
Self-citationAcute myeloid leukaemia genomics
Medinger, M., & Passweg, J. R. (2017) · British Journal of Haematology · doi:10.1111/bjh.14823 · Cited by 98
Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing
Rana, H. Q., Gelman, R. S., LaDuca, H., McFarland, R. E., Dalton, E., Thompson, J. D., Speare, V., Dolinsky, J. S., Chao, E., & Garber, J. E. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy001 · Cited by 96
New Insights from Studies of Clonal Hematopoiesis
Gibson, C. J., & Steensma, D. P. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3044 · Cited by 97
Age influences on the molecular presentation of tumours
Li, C. H., Haider, S. A., & Boutros, P. C. (2022) · Nature Communications · doi:10.1038/s41467-021-27889-y · Cited by 98
Epigenetic traits inscribed in chromatin accessibility in aged hematopoietic stem cells
Itokawa, N., Oshima, M., Koide, S., Takayama, N., Kuribayashi, W., Nakajima‐Takagi, Y., Aoyama, K., Yamazaki, S., Yamaguchi, K., Furukawa, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30440-2 · Cited by 102
Discovering the drivers of clonal hematopoiesis
Pich, O., Reyes-Salazar, I., González-Pérez, A., & López-Bigas, N. (2022) · Nature Communications · doi:10.1038/s41467-022-31878-0 · Cited by 100
Genomics of chronic neutrophilic leukemia
Maxson, J. E., & Tyner, J. W. (2016) · Blood · doi:10.1182/blood-2016-10-695981 · Cited by 95
Chen, X., & Wood, B. L. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.09.006 · Cited by 94
Severson, E. A., Riedlinger, G., Connelly, C. F., Vergilio, J., Goldfinger, M., Ramkissoon, S. H., Frampton, G. M., Ross, J. S., Fratella-Calabrese, A., Gay, L. M., et al. (2018) · Blood · doi:10.1182/blood-2018-03-840629 · Cited by 94
Premature Aging in Young Cancer Survivors
Armenian, S. H., Gibson, C. J., Rockne, R. C., & Ness, K. K. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy229 · Cited by 95
Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome
Bono, E. B., McLornan, D. P., Travaglino, E., Gandhi, S., Gallì, A., Khan, A. A., Kulasekararaj, A. G., Boveri, E., Raj, K. K., Elena, C., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0457-1 · Cited by 93
Batalini, F., Peacock, E. G., Stobie, L., Robertson, A., Garber, J. E., Weitzel, J. N., & Tung, N. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1193-1 · Cited by 94
Tercan, H., Riksen, N. P., Joosten, L. A. B., Netea, M. G., & Bekkering, S. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314212 · Cited by 97
Gurnari, C., Pagliuca, S., Prata, P. H., Galimard, J., Catto, L. F. B., Larcher, L., Sébert, M., Allain, V., Patel, B. J., Durmaz, A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00710 · Cited by 94
SanMiguel, J. M., Eudy, E., Loberg, M. A., Young, K. A., Mistry, J. J., Mujica, K. D., Schwartz, L. S., Stearns, T. M., Challen, G. A., & Trowbridge, J. J. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0086 · Cited by 95
Clonal Hematopoiesis and Risk of Incident Lung Cancer
Tian, R., Wiley, B. J., Liu, J., Zong, X., Truong, B. M. T., Zhao, S., Uddin, M. M., Niroula, A., Miller, C. A., Mukherjee, S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00857 · Cited by 96
Self-citationLin, A. E., Bapat, A. C., Xiao, L., Niroula, A., Ye, J., Wong, W. J., Agrawal, M., Farady, C. J., Boettcher, A., Hergott, C. A., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.065597 · Cited by 96
Self-citationTierney, M. T., Stec, M. J., Rulands, S., Simons, B. D., & Sacco, A. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2017.11.009 · Cited by 92
Genetics of human longevity within an eco-evolutionary nature-nurture framework
Giuliani, C., Garagnani, P., & Franceschi, C. (2018) · Circulation Research · doi:10.1161/circresaha.118.312562 · Cited by 92
Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans
Kaasinen, E., Kuismin, O., Rajamäki, K., Ristolainen, H., Aavikko, M., Kondelin, J., Saarinen, S., Berta, D. G., Katainen, R., Hirvonen, E. A. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09198-7 · Cited by 92
Malcovati, L., & Cazzola, M. (2015) · Hematology · doi:10.1182/asheducation-2015.1.299 · Cited by 96
Colchicine prevents accelerated atherosclerosis in TET2 -mutant clonal haematopoiesis
Zuriaga, M. A., Yu, Z., Matesanz, N., Truong, B. M. T., Ramos-Neble, B. L., Lopez, M., Uddin, M. M., Nakao, T., Niroula, A., Zorita, V., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae546 · Cited by 98
Self-citationYin, S., Gambe, R. G., Sun, J., Martinez, A. Z., Cartun, Z. J., Regis, F. F., Wan, Y., Fan, J., Brooks, A. N., Herman, S. E. M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.013 · Cited by 92
Self-citationDivergent Effects of Dnmt3a and Tet2 Mutations on Hematopoietic Progenitor Cell Fitness
Ostrander, E. L., Kramer, A. C., Mallaney, C., Celik, H., Koh, W. K., Fairchild, J., Haussler, E., Zhang, C. R., & Challen, G. A. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.02.011 · Cited by 97
Haring, B., Reiner, A. P., Liu, J., Tobias, D. K., Whitsel, E. A., Berger, J. S., Desai, P. M., Wassertheil-Smoller, S. W., LaMonte, M. J., Hayden, K. M., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.018789 · Cited by 92
Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease
Dawoud, A. A. Z., Gilbert, R. D., Tapper, W., & Cross, N. C. P. (2021) · Leukemia · doi:10.1038/s41375-021-01382-3 · Cited by 91
Lauer, E. M., Mutter, J., & Scherer, F. (2022) · Leukemia · doi:10.1038/s41375-022-01618-w · Cited by 92
Clonal hematopoiesis of indeterminate potential is associated with acute kidney injury
Vlasschaert, C., Robinson‐Cohen, C., Chen, J., Akwo, E. A., Parker, A., Silver, S. A., Bhatraju, P. K., Poisner, H. M., Cao, S., Jiang, M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02854-6 · Cited by 91
Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias
Gibson, C. J., Kennedy, J. A., Nikiforow, S., Kuo, F. C., Alyea, E. P., Ho, V. T., Ritz, J., Soiffer, R. J., Antin, J. H., & Lindsley, R. C. (2017) · Blood · doi:10.1182/blood-2017-01-764951 · Cited by 92
Self-citationDonor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation
Gondek, L. P., Zheng, G., Ghiaur, G., Dezern, A. E., Matsui, W. H., Yegnasubramanian, S., Lin, M.-T., Levis, M. J., Eshleman, J. R., Varadhan, R., et al. (2016) · Leukemia · doi:10.1038/leu.2016.63 · Cited by 92
Identification of cell-type-specific mutations in nodal T-cell lymphomas
Nguyen, T. B., Sakata‐Yanagimoto, M., Asabe, Y., Matsubara, D., Kano, J., Yoshida, K., Shiraishi, Y., Chiba, K., Tanaka, H., Miyano, S., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2016.122 · Cited by 92
Driver mutations in acute myeloid leukemia
Kishtagari, A., Levine, R. L., & Viny, A. D. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000567 · Cited by 100
Tocchetti, C. G., Ameri, P., de Boer, R. A., D’Alessandra, Y., Russo, M., Sorriento, D., Ciccarelli, M., Kiss, B., Bertrand, L., Dawson, D. K., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa222 · Cited by 94
Nakao, T., Bick, A. G., Taub, M. A., Zekavat, S. M., Uddin, M. M., Niroula, A., Carty, C. L., Lane, J., Honigberg, M. C., Weinstock, J. S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abl6579 · Cited by 91
Cardiovascular Disease in Myeloproliferative Neoplasms
Leiva, O., Hobbs, G. S., Ravid, K., & Libby, P. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.04.002 · Cited by 99
Clonal haematopoiesis of indeterminate potential predicts incident cardiac arrhythmias
Schuermans, A., Vlasschaert, C., Nauffal, V., Cho, S. M. J., Uddin, M. M., Nakao, T., Niroula, A., Klarqvist, M. D. R., Weeks, L. D., Lin, A. E., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad670 · Cited by 93
Self-citationUnidirectional association of clonal hematopoiesis with atherosclerosis development
Díez-Díez, M., Ramos-Neble, B. L., de la Barrera, J., Silla-Castro, J. C., Quintas, A., Vázquez, E., Rey-Martín, M. A., Izzi, B., Sánchez-García, L., García‐Lunar, I., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03213-1 · Cited by 94
The cell of origin and the leukemia stem cell in acute myeloid leukemia
Chopra, M., & Bohlander, S. K. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22805 · Cited by 95
When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review
Rodríguez, J. K., Ávila, J., Rolfo, C. D., Ruíz-Patiño, A., Russo, A., Ricaurte, L., Ordóñez‐Reyes, C., Arrieta, O. G., Zatarain-Barrón, Z. L., Recondo, G., et al. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00144-6 · Cited by 89
Siudeja, K., Nassari, S., Gervais, L., Skorski, P., Lameiras, S., Stolfa, D., Zande, M., Bernard, V., Frio, T. R., & Bardin, A. J. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.09.016 · Cited by 93
Radivoyevitch, T., Sachs, R. K., Gale, R. P., Molenaar, R. J., Brenner, D. J., Hill, B. T., Kalaycio, M. E., Carraway, H. E., Mukherjee, S., Sekeres, M. A., et al. (2015) · Leukemia · doi:10.1038/leu.2015.258 · Cited by 89
Berger, G., van den Berg, E., Sikkema‐Raddatz, B., Abbott, K. M., Sinke, R. J., Bungener, L. B., Mulder, A. B., & Vellenga, E. (2016) · Leukemia · doi:10.1038/leu.2016.310 · Cited by 90
Leukaemia 'firsts' in cancer research and treatment
Greaves, M. F. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.3 · Cited by 90
Single cell analysis of clonal architecture in acute myeloid leukaemia
Potter, N. E., Miraki‐Moud, F., Ermini, L., Titley, I., Vijayaraghavan, G., Papaemmanuil, E., Campbell, P. J., Gribben, J. G., Taussig, D. C., & Greaves, M. F. (2018) · Leukemia · doi:10.1038/s41375-018-0319-2 · Cited by 92
Togami, K., Chung, S. S., Madan, V., Booth, C. A. G., Kenyon, C. M., Cabal‐Hierro, L., Taylor, J., Kim, S. S., Griffin, G. K., Ghandi, M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1513 · Cited by 90
Steensma, D. P. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.04.001 · Cited by 91
Culberson, J. W., Kopel, J. J., Sehar, U., & Reddy, P. H. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102001 · Cited by 95
Yura, Y., Miura-Yura, E., Katanasaka, Y., Min, K.-D., Chavkin, N., Polizio, A. H., Ogawa, H., Horitani, K., Doviak, H., Evans, M. A., et al. (2021) · Circulation Research · doi:10.1161/circresaha.121.319314 · Cited by 87
Chen, Z., Amro, E. M., Becker, F. R., Hölzer, M., Rasa, S. M. M., Njeru, S. N., Han, B., Sanzo, S. D., Chen, Y.-L., Tang, D., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20181505 · Cited by 88
Garcia‐Manero, G., Abaza, Y., Takahashi, K., Medeiros, B. C., Arellano, M. L., Khaled, S. K., Patnaik, M. M., Odenike, O. M., Sayar, H., Tummala, M. K., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018027409 · Cited by 88
Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years
van Zeventer, I. A., Salzbrunn, J. B., de Graaf, A. O., van der Reijden, B. A., Boezen, H. M., Vonk, J. M., van der Harst, P., Schuringa, J. J., Jansen, J. H., & Huls, G. A. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004062 · Cited by 88
Shah, Y., Priore, S. F., Li, Y., Tang, C. N., Nicholas, P., Kurre, P., Olson, T. S., & Babushok, D. V. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004201 · Cited by 88
Azacytidine Treatment for VEXAS Syndrome
Raaijmakers, M. H. G. P., Hermans, M., Aalbers, A., Rijken, M., Dalm, V. A. S. H., van Daele, P., & Valk, P. J. M. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000661 · Cited by 90
Blockade of IL-6 signaling alleviates atherosclerosis in Tet2-deficient clonal hematopoiesis
Liu, W., Yalçınkaya, M., Fernández-Maestre, I., Olszewska, M., Ampomah, P. B., Heimlich, J. B., Wang, R., Vela, P. S., Xiao, T., Bick, A. G., et al. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00281-3 · Cited by 91
Defining the clinical validity of genes reported to cause pulmonary arterial hypertension
Welch, C. L., Aldred, M. A., Balachandar, S., Dooijes, D., Eichstaedt, C. A., Gräf, S., Houweling, A. C., Machado, R. D., Pandya, D., Prapa, M., et al. (2023) · Genetics in Medicine · doi:10.1016/j.gim.2023.100925 · Cited by 92
Readers of DNA methylation, the MBD family as potential therapeutic targets
Ginder, G. D., & Williams, D. C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.002 · Cited by 92
Busque, L., Sun, M., Buscarlet, M., Ayachi, S., Feroz Zada, Y., Provost, S., Bourgoin, V., Mollica, L., Meisel, M., Hinterleitner, R., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000770 · Cited by 87
Telomerase abrogates aneuploidy‐induced telomere replication stress, senescence and cell depletion
Meena, J. K., Cerutti, A., Beichler, C., Morita, Y., Bruhn, C., Kumar, M., Kraus, J. M., Speicher, M. R., Wang, Z., Kestler, H. A., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490070 · Cited by 87
Somatic clonal evolution: A selection-centric perspective
Scott, J. G., & Marusyk, A. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.01.006 · Cited by 87
Babushok, D. V., Duke, J. L., Xie, H. M., Stanley, N. L., Atienza, J., Perdigones, N., Nicholas, P., Ferriola, D., Li, Y., Huang, H., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010918 · Cited by 90
Hu, Y., Alden, R. S., Odegaard, J. I., Fairclough, S. R., Chen, R., Heng, J. C., Feeney, N. B., Nagy, R. J., Shah, J. M., Ulrich, B. C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1745 · Cited by 86
Cardiovascular Disease and Cancer: Is There Increasing Overlap?
Vincent, L. L., Leedy, D. J., Masri, S. C., & Cheng, R. K.-H. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0796-0 · Cited by 88
Clinical implications of recurrent gene mutations in acute myeloid leukemia
Yu, J., Li, Y., Zhang, D., Wan, D., & Jiang, Z. (2020) · Experimental Hematology and Oncology · doi:10.1186/s40164-020-00161-7 · Cited by 90
A six-attribute classification of geneticmosaicism
Martínez‐Glez, V., Tenorio, J. A., Nevado, J., Gordo, G., Rodríguez‐Laguna, L., Feito, M., de Lucas, R., Jurado, L. A. P., Ruiz‐Pérez, V. L., Torrelo, A., et al. (2020) · Genetics in Medicine · doi:10.1038/s41436-020-0877-3 · Cited by 88
Genetic modification of inflammation- and clonal hematopoiesis–associated cardiovascular risk
Yu, Z., Fidler, T. P., Ruan, Y., Vlasschaert, C., Nakao, T., Uddin, M. M., Mack, T., Niroula, A., Heimlich, J. B., Zekavat, S. M., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci168597 · Cited by 91
Self-citationPrecision cancer medicine: Concepts, current practice, and future developments
Edsjö, A., Holmquist, L., Geoerger, B., Nowak, F., Gomon, G., Alix‐Panabières, C., Staaf, J., Ploeger, C., Lassen, U., Tourneau, C. L., et al. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13709 · Cited by 91
Aging of hematopoietic stem cells: DNA damage and mutations?
Moehrle, B., & Geiger, H. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.06.253 · Cited by 87
Managing Clonal Hematopoiesis in Patients With Solid Tumors
Bolton, K. L., Gillis, N., Coombs, C. C., Takahashi, K., Zehir, A., Bejar, R. L., Garcia‐Manero, G., Futreal, P. A., Jensen, B. C., Diaz, L. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00331 · Cited by 87
Selfish mutations dysregulating RAS-MAPK signaling are pervasive in aged human testes
Maher, G. J., Ralph, H. K., Ding, Z., Koelling, N., Mlcochova, H., Giannoulatou, E., Dhami, P., Paul, D. S., Stricker, S. H., Beck, S., et al. (2018) · Genome Research · doi:10.1101/gr.239186.118 · Cited by 85
CHIP, ICUS, CCUS and other four-letter words
Bejar, R. L. (2017) · Leukemia · doi:10.1038/leu.2017.181 · Cited by 90
Greif, P. A., Hartmann, L., Vosberg, S., Stief, S. M., Mattes, R., Hellmann, I., Metzeler, K. H., Herold, T., Bamopoulos, S. A., Kerbs, P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2344 · Cited by 88
Clonal Hematopoiesis of Indeterminate Potential Reshapes Age-Related CVD
Khetarpal, S. A., Qamar, A., Bick, A. G., Fuster, J. J., Kathiresan, S., Jaiswal, S., & Natarajan, P. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.05.045 · Cited by 88
Self-citationMutations in spliceosome genes and therapeutic opportunities in myeloid malignancies
Taylor, J., & Lee, S. C.-W. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22784 · Cited by 88
Fang, S., Li, J., Xiao, Y., Lee, M., Guo, L., Han, W., Li, T., Hill, M. C., Hong, T., Mo, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12325-z · Cited by 89
Sleep exerts lasting effects on hematopoietic stem cell function and diversity
McAlpine, C. S., Kiss, M. G., Zuraikat, F. M., Cheek, D. M., Schiroli, G., Amatullah, H., Huynh, P., Bhatti, M. Z., Wong, L. P., Yates, A. G., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220081 · Cited by 92
Regulation of hematopoietic development by ZBTB transcription factors
Maeda, T. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2035-x · Cited by 88
Cole, C. B., Russler-Germain, D. A., Ketkar, S., Verdoni, A. M., Smith, A. M., Bangert, C. V., Helton, N. M., Guo, M., Klco, J. M., O’Laughlin, S., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93041 · Cited by 84
Ochi, Y., Yoshida, K., Huang, Y., Kuo, M., Nannya, Y., Sasaki, K., Mitani, K., Hosoya, N., Hiramoto, N., Ishikawa, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23097-w · Cited by 85
Cobo, I., Tanaka, T. N., Glass, C. K., & Yeang, C. (2021) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000688 · Cited by 90
Chi, K. N., Barnicle, A., Sibilla, C., Lai, Z., Corcoran, C., Barrett, J. C., Adelman, C. A., Qiu, P., Easter, A., Dearden, S. P., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0931 · Cited by 85
Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD)
Sun, Q.-Y., Ding, L.-W., Tan, K. T., Chien, W., Mayakonda, A., Lin, D.-C., Loh, X.-Y., Xiao, J.-F., Meggendorfer, M., Alpermann, T., et al. (2016) · Leukemia · doi:10.1038/leu.2016.160 · Cited by 87
Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment
Comen, E. A., Bowman, R. L., & Kleppe, M. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00056 · Cited by 87
Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma
Yoo, H. Y., Kim, N., Kim, W. S., Lee, S., Kim, S., Kang, S. Y., Jang, H.-Y., Lee, J. E., Kim, J., Kim, S. J., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.139253 · Cited by 88
Kon, A., Yamazaki, S., Nannya, Y., Kataoka, K., Ota, Y., Nakagawa, M. M., Yoshida, K., Shiozawa, Y., Morita, M., Yoshizato, T., et al. (2017) · Blood · doi:10.1182/blood-2017-01-762393 · Cited by 90
Kuendgen, A., Nomdedéu, M., Tuechler, H., Garcia‐Manero, G., Komrokji, R. S., Sekeres, M. A., Porta, M. G. D., Cazzola, M., Dezern, A. E., Roboz, G. J., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0917-7 · Cited by 83
Innate and adaptive immunity: the understudied driving force of heart valve disease
Bartoli‐Leonard, F., Zimmer, J., & Aïkawa, E. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab273 · Cited by 90
Murthy, G. S. G., Kim, S., Hu, Z., Estrada‐Merly, N., Abid, M. B., Aljurf, M. D., Bacher, U., Badawy, S. M., Beitinjaneh, A., Bredeson, C., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.6846 · Cited by 83
Lopez‐Mattei, J., Yang, E. H., Baldassarre, L. A., Agha, A. M., Blankstein, R., Choi, A., Chen, M. Y., Meyersohn, N. M., Daly, R. P., Slim, A. M., et al. (2022) · Journal of cardiovascular computed tomography · doi:10.1016/j.jcct.2022.09.002 · Cited by 85
McClatchy, J., Strogantsev, R., Wolfe, E., Lin, H., Mohammadhosseini, M., Davis, B. A., Eden, C. O., Goldman, D., Fleming, W., Conley, P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43697-y · Cited by 86
Rosai–Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation
Shanmugam, V., Margolskee, E. M., Kluk, M., Giorgadze, T., & Orazi, A. (2016) · Head and Neck Pathology · doi:10.1007/s12105-016-0709-6 · Cited by 83
Self-citationWhen Genome Maintenance Goes Badly Awry
Kass, E. M., Moynahan, M. E., & Jasin, M. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.05.021 · Cited by 84
Metadata
- Authors
- Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., Higgins, J. M., Moltchanov, V., Kuo, F. C., Kluk, M. J., Henderson, B., Kinnunen, L., Koistinen, H. A., Ladenvall, C., Getz, G., Correa, A., Banahan, B. F., Gabriel, S., Kathiresan, S., Stringham, H. M., McCarthy, M. I., Boehnke, M., Tuomilehto, J., Haiman, C., Groop, L., Atzmon, G., Wilson, J. G., Neuberg, D., Altshuler, D., & Ebert, B. L.
- Affiliations
- Brigham and Women's Hospital (US)
- Broad Institute (US)
- University of Helsinki (FI)
- University of Southern California (US)
- Helsinki University Hospital (FI)
- Lund University (SE)
- University of Mississippi Medical Center (US)
- University of Michigan (US)
- Centre for Human Genetics (GB)
- Universität für Weiterbildung Krems (AT)
- Albert Einstein College of Medicine (US)
- Harvard University (US)
- ORCID
- Jaiswal, Siddhartha
- Fontanillas, Pierre
- Flannick, Jason
- Manning, Alisa
- Mar, Brenton G.
- Lindsley, R. Coleman
- Mermel, Craig H.
- Chavez, Alejandro
- Higgins, John M.
- Kuo, Frank C.
- Kluk, Michael J.
- Kinnunen, Leena
- Koistinen, Heikki A.
- Ladenvall, Claes
- Getz, Gad
- Correa, Adolfo
- Banahan, Benjamin F.
- Gabriel, Stacey
- Kathiresan, Sekar
- Stringham, Heather M.
- McCarthy, Mark I.
- Boehnke, Michael
- Tuomilehto, Jaakko
- Groop, Leif
- Atzmon, Gil
- Wilson, James G.
- Neuberg, Donna
- Altshuler, David
- Ebert, Benjamin L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-25
- Volume
- 371
- Issue
- 26
- Pages
- 2488-2498
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4306669
- OpenAlex
- W2149858388
- Cited by
- 4,841
- References
- 48
- Citations by year
- 2026: 423 · 2025: 446 · 2024: 494 · 2023: 521 · 2022: 536 · 2021: 520 · 2020: 454 · 2019: 387 · 2018: 356 · 2017: 301 · 2016: 237 · 2015: 151 · 2014: 6
- FWCI
- 164.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Funders
- Wellcome Trust (090367, 085475, 098381, 090532, 083948)
- National Institutes of Health (5rc2dk088389-02)
- National Institute on Aging (R01AG042188, P01AG021654, P30AG038072)
- National Heart, Lung, and Blood Institute (R01HL082945, T32HL066987)
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (T32CA009216, T32CA009172, P01CA066996)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK085526, U01DK085584, DP2DK098087, U01DK085501, U01DK085524, RC2-DK088389, U01DK085545, DK088389, P30DK020572)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Keywords
- age-related clonal hematopoiesis, somatic mutations, all-cause mortality, coronary artery disease, ischemic stroke, cardiovascular disease, DNMT3A, TET2, ASXL1, peripheral blood, aging
- MeSH terms
- Adult, Age Factors, Aged, Aged, 80 and over, Blood, Cell Transformation, Neoplastic, Clone Cells, DNA Mutational Analysis, Hematopoiesis, Hematopoietic Stem Cells, Humans, Middle Aged, Mutation, Risk Factors, Hematologic Neoplasms, Young Adult, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
